When the two tumour groups were combined, mutations were most frequently observed in TP53 (86%), APC (44%), KRAS (36%), PIK3CA (9%), SMAD4 (9%), NRAS (9%) and 4% for FBXW7, BRAF, GNAS and CDH1. Here, KRAS is linked to neoplasm.